Multiplicity and the marginal benefits of bevacizumab in malignant solid tumours

Lignende værker

• Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
  af: Koumarianou, Anna, et al.
  Udgivet: (2012)
• Marginal benefits of adding formoterol
  af: Lipworth, B, et al.
  Udgivet: (2002)
• The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada
  af: Drucker, A., et al.
  Udgivet: (2008)
• Surgical margins for borderline and malignant phyllodes tumours
  af: Thind, A, et al.
  Udgivet: (2020)
• Multiple Primary Malignant Tumours
  af: Tees, J. G.
  Udgivet: (1961)